Target | Itgam |
Immunogen | Mouse integrin alpha M |
Species Reactivity | Mouse |
Application | IP, IF, FuncS, Cell Penetration |
Clone | WJ507 |
Host Animal | Llama |
Isotype | sdAb |
Clonality | Monoclonal |
Class | Primary |
Concentration | 1 mg/mL |
Conjugation | snGFP |
Storage Condition | Store at 4°C for short term (1-2 weeks). Aliquot and store at -20°C for long term. Avoid repeated freeze/thaw cycles. |
Target Background | Integrin alpha M (ITGAM) is one protein subunit that forms the heterodimeric integrin alpha-M beta-2 (αMβ2) molecule, also known as macrophage-1 antigen (Mac-1) or complement receptor 3 (CR3). ITGAM is also known as CR3A, and cluster of differentiation molecule 11B (CD11B). The second chain of αMβ2 is the common integrin β2 subunit known as CD18, and integrin αMβ2 thus belongs to the β2 subfamily (or leukocyte) integrins. αMβ2 is expressed on the surface of many leukocytes involved in the innate immune system, including monocytes, granulocytes, macrophages, and natural killer cells. It mediates inflammation by regulating leukocyte adhesion and migration and has been implicated in several immune processes such as phagocytosis, cell-mediated cytotoxicity, chemotaxis and cellular activation. It is involved in the complement system due to its capacity to bind inactivated complement component 3b (iC3b). The ITGAM (alpha) subunit of integrin αMβ2 is directly involved in causing the adhesion and spreading of cells but cannot mediate cellular migration without the presence of the β2 (CD18) subunit. |
Target Synonym | ITGAM; integrin alpha M; CR3; CR3A; MAC1; Cd11b; Ly-40; Mac-1; Mac-1a; CD11b/CD18; F730045J24Rik; integrin alpha-M; Mac-1 alpha; CD11B (p170); CR-3 alpha chain; macrophage antigen alpha; complement receptor type 3; leukocyte adhesion receptor MO1; CD11 an |
Gene ID | 16409 |
UniProt ID | E9Q604 |
If you can't find your product on this list? Please directly send email to
For Research Use Only. Not for diagnostic or therapeutic applications.
Enter your email here to subscribe.
Submit
Follow us on